Our lead product VAL-1000 is currently in a Phase I/II clinical trial and is initially being developed to treat patients with Acute Myeloid Leukaemia (AML).
The clinical trial is being conducted at The Alfred Hospital in Melbourne, Australia under the supervision of Principal Investigator Dr Andrew Wei.
VAL-1000 is being co-developed with Allyence Research Inc. in California, USA. VAL-1000 is a synthetic derivative of a natural product, with significant prior human exposure. It is an orally available, effective small molecule chemotherapeutic agent with very low toxicity and in vitro and in vivo activity in Acute Myeloid Leukaemia (AML) via a potentially novel mechanism of action.